A Clinical Trial of Tri-Iodothyronine as a Hormone Potentiator in Advanced Breast Cancer
1962

Tri-Iodothyronine as a Hormone Potentiator in Advanced Breast Cancer

Sample size: 12 publication Evidence: low

Author Information

Author(s): B. A. Stoll

Primary Institution: Peter MacCallum Clinic, Melbourne, Australia

Hypothesis

Can tri-iodothyronine (T3) combined with oestrogen improve treatment outcomes in advanced breast cancer?

Conclusion

The study found no evidence that adding thyroid or T3 to oestrogen therapy improves outcomes in advanced breast cancer.

Supporting Evidence

  • Only 3 out of 12 patients showed any regression of tumors.
  • Patients who had previously responded to oestrogens did not respond to the addition of T3.
  • Some patients experienced severe side effects leading to treatment discontinuation.

Takeaway

Doctors wanted to see if a thyroid hormone could help women with advanced breast cancer when other treatments weren't working, but it didn't help.

Methodology

Patients with advanced breast cancer were treated with oestrogen and either thyroid extract or T3 for up to three months.

Limitations

The small sample size and the lack of control group limit the findings.

Participant Demographics

All participants were postmenopausal women with advanced breast cancer.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication